Perturbed membrane-binding compounds and methods of using the same
申请人:Ziv Ilan
公开号:US20050158239A1
公开(公告)日:2005-07-21
The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
METHOD FOR PRODUCTION OF SUBSTITUTED ALKYL MALONIC ESTERS AND DERIVATIVES THEREOF
申请人:Friedman Gad
公开号:US20120029223A1
公开(公告)日:2012-02-02
Substituted alkyl methyl malonate compounds are produced in an essentially one step method, the method suitable for large scale production of alkyl malonate compounds. According to one embodiment the method comprises reacting a methyl malonate with a di-functional, doubly tosylated, alkyl chain.
Perturbed Membrane-Binding Compounds And Methods Of Using The Same
申请人:Ziv Ilan
公开号:US20080279774A1
公开(公告)日:2008-11-13
The present invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, such as cells undergoing apoptosis or activated platelets. The invention further provides methods for utilizing said compounds in medical practice, for diagnostic and therapeutic purposes.
COMPOUNDS AND METHODS FOR DETECTION OF CELLS
申请人:Shirvan Anat
公开号:US20100035296A1
公开(公告)日:2010-02-11
The invention relates to compounds comprising an ester group for the detection in vivo of cells undergoing cell death (“dying cells”) such as, for example, cells undergoing apoptosis. These compounds are selectively retained in dying cells relative to normal cells. Thus, the compounds may be used in the detection, diagnosis and treatment of clinical conditions manifested by a cell death process.
PERTURBED MEMBRANE-BINDING COMPOUNDS AND METHODS OF USING THE SAME
申请人:ZIV Ilan
公开号:US20110257434A1
公开(公告)日:2011-10-20
The invention relates to compounds that selectively bind to cells undergoing perturbations and alterations of their normal plasma membrane organization, i.e., cells undergoing cell death, apoptotic cells or activated platelets. The invention further provides methods for utilizing the compounds in medical practice, for diagnostic and therapeutic purposes.